Okyo Pharma LTD (OKYO) SEC Filings — 2025

Filings

• OKYO Pharma Rings Nasdaq Opening Bell — 6-K · Dec 19, 2025
• Okyo Pharma LTD 6-K Filing — 6-K · Dec 15, 2025
• Okyo Pharma LTD 6-K Filing — 6-K · Dec 11, 2025
• Okyo Pharma LTD 6-K Filing — 6-K · Dec 3, 2025
• Okyo Pharma LTD 6-K Filing — 6-K · Nov 21, 2025
• Okyo Pharma LTD 6-K Filing — 6-K · Nov 18, 2025
• OKYO Pharma CEO to Speak at BIO-Europe Conference — 6-K · Oct 29, 2025
• OKYO Pharma: Chairman's Entity Buys 210K Shares — 6-K · Oct 16, 2025
• OKYO Pharma Starts 100-Patient Trial for Urcosimod — 6-K · Sep 22, 2025
• OKYO Pharma Amends 20-F/A to Include Clawback Policy — 20-F/A · Aug 12, 2025
• OKYO Pharma Navigates Pre-Revenue Phase, Bolsters Capital for R&D — 20-F · Jul 18, 2025
• OKYO Pharma Secures $1.9M Non-Dilutive Funding — 6-K · Jul 17, 2025
• OKYO Pharma Announces Positive Phase 2 Data for Urcosimod — 6-K · Jul 16, 2025
• OKYO Pharma CEO to Present on Urcosimod at Bio International Convention — 6-K · Jun 11, 2025
• OKYO Pharma CEO to Present at GPCR Drug Discovery Summit — 6-K · May 19, 2025
• OKYO Pharma's Urcosimod Gets FDA Fast Track for Pain — 6-K · May 1, 2025
• OKYO Pharma Accelerates Urcosimod Development for NCP — 6-K · Apr 30, 2025
• OKYO Pharma's Urcosimod Shows Long-Term Stability — 6-K · Mar 31, 2025
• OKYO Pharma Seeks FDA Fast Track for Neuropathic Pain Drug — 6-K · Mar 10, 2025
• OKYO Pharma's OK-101 Asset Named Urcosimod — 6-K · Feb 12, 2025
• OKYO Pharma CEO Buys Shares — 6-K · Jan 31, 2025
• OKYO Pharma Ltd Reports H1 2024 Financials and Business Update — 6-K · Jan 29, 2025
• OKYO Pharma Secures $1.4M Non-Dilutive Funding — 6-K · Jan 22, 2025